1184MO Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)

Authors:
  • GKG. Klöppel
    G. Klöppel
Publisher website
Google Scholar
Abstract
No abstract available